The Myotonic Dystrophy Type 1 Network (Red-DM) launches its official webpage

The Nucleic Acids Chemistry group, led by Prof. Ramon Eritja’s of the IQAC (CSIC), is participating in a multidisciplinary network for Myotonic Dystrophy Type 1 (DM1) with other 6 research groups from Valencia (INCLIVA, BIOTECMED, IIS La Fe), Barcelona (IGTP, IBEC) and Bilbao (IIS BioBiskaia, CSUR-Biodonostia) in the development of novel DNA/RNA-based therapies (oligonucleotides).

During the last five years, oligonucleotides have provided a dozen novel drugs to fulfill one of the dreams of mankind, being able to successfully treat inherited rare diseases. This project aims to catalyze advancements in therapeutic interventions and ultimately improve outcomes for people affected by this debilitating disease.

On the International Day of Rare Diseases, the Myotonic Dystrophy Type 1 (DM1) Network is launching its official webpage (RED-DM website), a server for disseminating information, fostering collaboration, and facilitating communication between researchers, clinicians, and stakeholders invested in the fight against DM1. It provides a platform to showcase ongoing research efforts, share resources, and promote dialogue to accelerate progress in understanding and treating this complex disease.